Wockhardt Ltd
NSE:WOCKPHARMA
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
1 155.5
1 831.1
|
| Price Target |
|
We'll email you a reminder when the closing price reaches INR.
Choose the stock you wish to monitor with a price alert.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Walmart Inc
NYSE:WMT
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
Operating Margin
Wockhardt Ltd
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Operating Margin Across Competitors
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| IN |
W
|
Wockhardt Ltd
NSE:WOCKPHARMA
|
220.8B INR |
7%
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
985.4B USD |
44%
|
|
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP |
3%
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
506.1B USD |
27%
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
252.7B CHF |
34%
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
209.2B GBP |
24%
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
206.9B CHF |
33%
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
246.7B USD |
38%
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.4T DKK |
42%
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
209B USD |
11%
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
142.4B USD |
29%
|
Wockhardt Ltd
Glance View
Wockhardt Ltd., founded in the early 1960s, has woven its story with a blend of cutting-edge research and an unwavering commitment to healthcare. Emerging from modest beginnings as a simple pharmaceutical company in India, Wockhardt evolved into a global player. The company carved out its niche in the life sciences sector, leveraging its strength in research and development to push the boundaries of pharmaceutical innovation. Its portfolio spans an array of products including generics, biosimilars, and a focus on pioneering antibiotics that combat the growing threat of drug-resistant bacteria. Central to Wockhardt’s narrative is its significant investment in biotechnology, which fuels its innovation pipeline. By focusing on difficult-to-manufacture drugs and addressing unmet medical needs, Wockhardt not only navigates the complex pharmaceutical landscape but also establishes itself as an indispensable partner in global healthcare. Financially, Wockhardt propels its operations forward through a diverse revenue stream derived from both domestic and international markets. Its business model capitalizes on manufacturing a broad spectrum of generics that cater to the needs of emerging and developed markets alike. The company’s strategic emphasis on research-oriented endeavors is fortified by its robust infrastructure of manufacturing facilities and research centers across multiple countries. This global network enables Wockhardt to efficiently scale production and distribute its pharmaceutical creations to a wide array of markets. By securing patents and maintaining a strong focus on specialty drugs, Wockhardt effectively balances its commitments to both shareholder value and societal health obligations, illustrating a nuanced dance between business acumen and healthcare advocacy.
See Also
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Based on Wockhardt Ltd's most recent financial statements, the company has Operating Margin of 7.3%.